Puneet Souda, an analyst from Leerink Partners, maintained the Buy rating on Natera (NTRA – Research Report). The associated price target was raised to $185.00.
Puneet Souda has given his Buy rating due to a combination of factors that highlight Natera’s strong market position and growth potential. Notably, Natera’s impressive financial performance is a key driver, with third-quarter revenues significantly surpassing expectations and reflecting a robust year-over-year growth. This performance is further bolstered by the success of their Signatera product, which has shown remarkable growth in the MRD market, both in terms of test volumes and revenue.
Additionally, Natera’s forward-looking strategies, such as raising their revenue guidance and maintaining a strong pipeline of clinical studies, contribute to a positive outlook. The potential for inclusion in key clinical guidelines and the ongoing expansion of coverage for their products further solidify their market leadership and future growth prospects. These elements combined underscore Souda’s confidence in Natera’s trajectory and support his Buy rating.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $185.00 price target.
Based on the recent corporate insider activity of 175 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTRA in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Natera (NTRA) Company Description:
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.
Read More on NTRA:
